Literature DB >> 18973345

Different thermodynamic binding mechanisms and peptide fine specificities associated with a panel of structurally similar high-affinity T cell receptors.

Lindsay L Jones1, Leremy A Colf, Alexander J Bankovich, Jennifer D Stone, Yi-Gui Gao, Choi Mui Chan, Raven H Huang, K Christopher Garcia, David M Kranz.   

Abstract

To understand the mechanisms that govern T cell receptor (TCR)-peptide MHC (pMHC) binding and the role that different regions of the TCR play in affinity and antigen specificity, we have studied the TCR from T cell clone 2C. High-affinity mutants of the 2C TCR that bind QL9-L(d) as a strong agonist were generated previously by site-directed mutagenesis of complementarity determining regions (CDRs) 1beta, 2alpha, 3alpha, or 3beta. We performed isothermal titration calorimetry to assess whether they use similar thermodynamic mechanisms to achieve high affinity for QL9-L(d). Four of the five TCRs examined bound to QL9-L(d) in an enthalpically driven, entropically unfavorable manner. In contrast, the high-affinity CDR1beta mutant resembled the wild-type 2C TCR interaction, with favorable entropy. To assess fine specificity, we measured the binding and kinetics of these mutants for both QL9-L(d) and a single amino acid peptide variant of QL9, called QL9-Y5-L(d). While 2C and most of the mutants had equal or higher affinity for the Y5 variant than for QL9, mutant CDR1beta exhibited 8-fold lower affinity for Y5 compared to QL9. To examine possible structural correlates of the thermodynamic and fine specificity signatures of the TCRs, the structure of unliganded QL9-L(d) was solved and compared to structures of the 2C TCR/QL9-L(d) complex and three high-affinity TCR/QL9-L(d) complexes. Our findings show that the QL9-L(d) complex does not undergo major conformational changes upon binding. Thus, subtle changes in individual CDRs account for the diverse thermodynamic and kinetic binding mechanisms and for the different peptide fine specificities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18973345      PMCID: PMC2680728          DOI: 10.1021/bi801349g

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  48 in total

1.  Distinct molecular mechanisms account for the specificity of two different T-cell receptors.

Authors:  Nadja Anikeeva; Tatiana Lebedeva; Michelle Krogsgaard; Sergey Y Tetin; Erik Martinez-Hackert; Spyros A Kalams; Mark M Davis; Yuri Sykulev
Journal:  Biochemistry       Date:  2003-04-29       Impact factor: 3.162

2.  Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation.

Authors:  Phillip D Holler; David M Kranz
Journal:  Immunity       Date:  2003-02       Impact factor: 31.745

3.  TCRs with high affinity for foreign pMHC show self-reactivity.

Authors:  Phillip D Holler; Lukasz K Chlewicki; David M Kranz
Journal:  Nat Immunol       Date:  2002-12-09       Impact factor: 25.606

4.  PHENIX: building new software for automated crystallographic structure determination.

Authors:  Paul D Adams; Ralf W Grosse-Kunstleve; Li Wei Hung; Thomas R Ioerger; Airlie J McCoy; Nigel W Moriarty; Randy J Read; James C Sacchettini; Nicholas K Sauter; Thomas C Terwilliger
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2002-10-21

5.  CDR3 loop flexibility contributes to the degeneracy of TCR recognition.

Authors:  Jean-Baptiste Reiser; Claudine Darnault; Claude Grégoire; Thomas Mosser; Gilbert Mazza; Alice Kearney; P Anton van der Merwe; Juan Carlos Fontecilla-Camps; Dominique Housset; Bernard Malissen
Journal:  Nat Immunol       Date:  2003-02-03       Impact factor: 25.606

6.  Interface-disrupting amino acids establish specificity between T cell receptors and complexes of major histocompatibility complex and peptide.

Authors:  Eric S Huseby; Frances Crawford; Janice White; Philippa Marrack; John W Kappler
Journal:  Nat Immunol       Date:  2006-10-15       Impact factor: 25.606

7.  A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule.

Authors:  Fleur E Tynan; Hugh H Reid; Lars Kjer-Nielsen; John J Miles; Matthew C J Wilce; Lyudmila Kostenko; Natalie A Borg; Nicholas A Williamson; Travis Beddoe; Anthony W Purcell; Scott R Burrows; James McCluskey; Jamie Rossjohn
Journal:  Nat Immunol       Date:  2007-01-28       Impact factor: 25.606

8.  Disparate thermodynamics governing T cell receptor-MHC-I interactions implicate extrinsic factors in guiding MHC restriction.

Authors:  Lauren K Ely; Travis Beddoe; Craig S Clements; Jacqueline M Matthews; Anthony W Purcell; Lars Kjer-Nielsen; James McCluskey; Jamie Rossjohn
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-14       Impact factor: 11.205

9.  Evidence that structural rearrangements and/or flexibility during TCR binding can contribute to T cell activation.

Authors:  Michelle Krogsgaard; Nelida Prado; Erin J Adams; Xiao-lin He; Dar-Chone Chow; Darcy B Wilson; K Christopher Garcia; Mark M Davis
Journal:  Mol Cell       Date:  2003-12       Impact factor: 17.970

10.  How much can a T-cell antigen receptor adapt to structurally distinct antigenic peptides?

Authors:  Catherine Mazza; Nathalie Auphan-Anezin; Claude Gregoire; Annick Guimezanes; Christine Kellenberger; Alain Roussel; Alice Kearney; P Anton van der Merwe; Anne-Marie Schmitt-Verhulst; Bernard Malissen
Journal:  EMBO J       Date:  2007-03-15       Impact factor: 11.598

View more
  15 in total

1.  Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors.

Authors:  David H Aggen; Adam S Chervin; Francis K Insaidoo; Kurt H Piepenbrink; Brian M Baker; David M Kranz
Journal:  Protein Eng Des Sel       Date:  2010-12-14       Impact factor: 1.650

2.  The same major histocompatibility complex polymorphism involved in control of HIV influences peptide binding in the mouse H-2Ld system.

Authors:  Samanthi Narayanan; David M Kranz
Journal:  J Biol Chem       Date:  2013-09-24       Impact factor: 5.157

3.  Methods for quantifying T cell receptor binding affinities and thermodynamics.

Authors:  Kurt H Piepenbrink; Brian E Gloor; Kathryn M Armstrong; Brian M Baker
Journal:  Methods Enzymol       Date:  2009-11-13       Impact factor: 1.600

Review 4.  Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.

Authors:  Akshata Udyavar; Terrence L Geiger
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2010-08-01       Impact factor: 4.291

5.  The energetic basis underpinning T-cell receptor recognition of a super-bulged peptide bound to a major histocompatibility complex class I molecule.

Authors:  Yu Chih Liu; Zhenjun Chen; Scott R Burrows; Anthony W Purcell; James McCluskey; Jamie Rossjohn; Stephanie Gras
Journal:  J Biol Chem       Date:  2012-02-16       Impact factor: 5.157

6.  Subtle changes at the variable domain interface of the T-cell receptor can strongly increase affinity.

Authors:  Preeti Sharma; David M Kranz
Journal:  J Biol Chem       Date:  2017-12-11       Impact factor: 5.157

7.  The effect of mutations on the alloreactive T cell receptor/peptide-MHC interface structure: a molecular dynamics study.

Authors:  Mikhail Y Wolfson; Kwangho Nam; Arup K Chakraborty
Journal:  J Phys Chem B       Date:  2011-06-09       Impact factor: 2.991

8.  TCR scanning of peptide/MHC through complementary matching of receptor and ligand molecular flexibility.

Authors:  William F Hawse; Soumya De; Alex I Greenwood; Linda K Nicholson; Jaroslav Zajicek; Evgenii L Kovrigin; David M Kranz; K Christopher Garcia; Brian M Baker
Journal:  J Immunol       Date:  2014-02-12       Impact factor: 5.422

9.  Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor.

Authors:  Jennifer D Stone; Adam S Chervin; Hans Schreiber; David M Kranz
Journal:  Biotechnol Prog       Date:  2012-10-18

10.  Subtle changes in TCRα CDR1 profoundly increase the sensitivity of CD4 T cells.

Authors:  Jennifer N Lynch; David L Donermeyer; K Scott Weber; David M Kranz; Paul M Allen
Journal:  Mol Immunol       Date:  2012-09-14       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.